Anke Biotechnology Secures Exclusive Distribution Rights for Desloratadine Citrate Disodium Oral Solution

Corporate Action
โดย CLS·Read original
Summary · why it matters

Anke Biotechnology announced that the company and its wholly-owned subsidiary Anhui Huasheng have signed an agreement with Hefei Yigong and Enruite. Enruite has authorized Anhui Huasheng to be the sole national distributor of the collaborative product Desloratadine Citrate Disodium Oral Solution, with the cooperation period lasting until December 31, 2042. This product is a unique domestic variety and the only Desloratadine Citrate Disodium oral solution formulation in China that has completed clinical trial verification for children aged six months and above. It can effectively meet the unmet clinical needs of young patients and fill a gap in the niche market.

Impact on stocks 1

Others▲ · 1 stocks
Anhui Anke BioTech Group
300009
▲ PositiveDemandrelevance

Anke's subsidiary gains exclusive distribution rights for a unique pediatric drug, expanding market reach and revenue potential.

Off-coverage companies 3

安徽华胜Private▲ Positive
Demandrelevance

Anhui Huasheng, as the sole national distributor, directly gains from the exclusive rights and long-term cooperation.

合肥医工Private▲ Positive
Demandrelevance

Hefei Yigong, as the authorizing party, benefits from Anke's distribution network for its product.

合肥恩瑞特药业有限公司Private▲ Positive
Demandrelevance

Enruite, as the authorizing party, benefits from Anke's distribution capabilities for its product.

© 2026 MarketDXNews